Literature DB >> 26202024

The prediction of immunological dysfunction during antiviral therapy for HCV after liver transplantation: can we improve outcomes?

Ji-Yuan Zhang1, Yuan-Yuan Li1, Zheng Zhang1, Fu-Sheng Wang2.   

Abstract

Entities:  

Year:  2013        PMID： 26202024     DOI： 10.1007/s12072-013-9474-8

Source DB:  PubMed          Journal:  Hepatol Int        ISSN： 1936-0533            Impact factor:   6.047


× No keyword cloud information.
  20 in total

1.  Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation.

Authors:  T Bizollon; P Pradat; J-Y Mabrut; S Radenne; C Ducerf; J Baulieux; J C Souquet; C Trepo
Journal:  Am J Transplant       Date:  2006-12-06       Impact factor: 8.086

2.  High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?

Authors:  S Berardi; F Lodato; A Gramenzi; A D'Errico; M Lenzi; A Bontadini; M C Morelli; M R Tamè; F Piscaglia; M Biselli; C Sama; G Mazzella; A D Pinna; G Grazi; M Bernardi; P Andreone
Journal:  Gut       Date:  2006-06-23       Impact factor: 23.059

3.  Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C.

Authors:  Inmaculada Fernández; Esperanza Ulloa; Francisco Colina; Manuel Abradelo; Carlos Jiménez; Alberto Gimeno; Juan Carlos Meneu; Carlos Lumbreras; José Antonio Solís-Herruzo; Enrique Moreno
Journal:  Liver Transpl       Date:  2009-08       Impact factor: 5.799

4.  The association between hepatitis C infection and survival after orthotopic liver transplantation.

Authors:  Lisa M Forman; James D Lewis; Jesse A Berlin; Harold I Feldman; Michael R Lucey
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

Review 5.  Immunosuppression and HCV recurrence after liver transplantation.

Authors:  Dimitrios N Samonakis; Giacomo Germani; Andrew K Burroughs
Journal:  J Hepatol       Date:  2011-09-29       Impact factor: 25.083

6.  Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation.

Authors:  Amandeep K Shergill; Mandana Khalili; Stephanie Straley; Kathy Bollinger; John P Roberts; Nancy A Ascher; Norah A Terrault
Journal:  Am J Transplant       Date:  2005-01       Impact factor: 8.086

Review 7.  Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies.

Authors:  E Xirouchakis; C Triantos; P Manousou; A Sigalas; V Calvaruso; A Corbani; G Leandro; D Patch; A Burroughs
Journal:  J Viral Hepat       Date:  2008-07-28       Impact factor: 3.728

8.  Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.

Authors:  José A Carrión; Miquel Navasa; Montserrat García-Retortillo; Juan Carlos García-Pagan; Gonzalo Crespo; Miquel Bruguera; Jaime Bosch; Xavier Forns
Journal:  Gastroenterology       Date:  2007-03-24       Impact factor: 22.682

9.  Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus.

Authors:  M Isabel Fiel; Kaushik Agarwal; Carmen Stanca; Nassim Elhajj; Nikolas Kontorinis; Swan N Thung; Thomas D Schiano
Journal:  Liver Transpl       Date:  2008-06       Impact factor: 5.799

10.  Long-term outcome of hepatitis C infection after liver transplantation.

Authors:  E J Gane; B C Portmann; N V Naoumov; H M Smith; J A Underhill; P T Donaldson; G Maertens; R Williams
Journal:  N Engl J Med       Date:  1996-03-28       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.